Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-07-29 DOI:10.2147/cmar.s474348

Luohang Ni, Jianing Xu, Quanpeng Li, Xianxiu Ge, Fei Wang, Xueting Deng, Lin Miao

{"title":"Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer","authors":"Luohang Ni, Jianing Xu, Quanpeng Li, Xianxiu Ge, Fei Wang, Xueting Deng, Lin Miao","doi":"10.2147/cmar.s474348","DOIUrl":null,"url":null,"abstract":"Abstract: Biliary tract cancer (BTC) represents a challenging malignancy characterized by aggressive behavior, high relapse rates, and poor prognosis. In recent years, immunotherapy has revolutionized the treatment landscape for various cancers, but its efficacy in BTC remains limited. This article provides a comprehensive overview of the advances in preclinical and clinical studies of immunotherapy for BTC. We explore the potential of immune checkpoint inhibitors in reshaping the management of BTC. Despite disappointing results thus far, ongoing clinical trials are investigating the combination of immunotherapy with other treatment modalities. Furthermore, research on the tumor microenvironment has unveiled novel targets for immunotherapeutic interventions. By understanding the current state of immunotherapy in BTC and highlighting future directions, this article aims to fuel further exploration and ultimately improve patient outcomes in this challenging disease. Keywords: biliary tract cancer, cancer immunotherapy, tumor microenvironment, immune checkpoint inhibitors, clinical trials ","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":"56 1","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/cmar.s474348","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract: Biliary tract cancer (BTC) represents a challenging malignancy characterized by aggressive behavior, high relapse rates, and poor prognosis. In recent years, immunotherapy has revolutionized the treatment landscape for various cancers, but its efficacy in BTC remains limited. This article provides a comprehensive overview of the advances in preclinical and clinical studies of immunotherapy for BTC. We explore the potential of immune checkpoint inhibitors in reshaping the management of BTC. Despite disappointing results thus far, ongoing clinical trials are investigating the combination of immunotherapy with other treatment modalities. Furthermore, research on the tumor microenvironment has unveiled novel targets for immunotherapeutic interventions. By understanding the current state of immunotherapy in BTC and highlighting future directions, this article aims to fuel further exploration and ultimately improve patient outcomes in this challenging disease.

Keywords: biliary tract cancer, cancer immunotherapy, tumor microenvironment, immune checkpoint inhibitors, clinical trials

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

关注免疫细胞：胆道癌免疫疗法的最新进展

摘要：胆道癌（BTC）是一种具有挑战性的恶性肿瘤，其特点是侵袭性强、复发率高、预后差。近年来，免疫疗法彻底改变了各种癌症的治疗格局，但其对 BTC 的疗效仍然有限。本文全面概述了免疫疗法治疗 BTC 的临床前和临床研究进展。我们探讨了免疫检查点抑制剂在重塑 BTC 治疗中的潜力。尽管迄今为止的结果令人失望，但正在进行的临床试验正在研究免疫疗法与其他治疗方式的结合。此外，对肿瘤微环境的研究揭示了免疫治疗干预的新靶点。通过了解 BTC 免疫疗法的现状并强调未来的发展方向，本文旨在推动进一步的探索，并最终改善这种具有挑战性疾病的患者预后。关键词：胆道癌；癌症免疫疗法；肿瘤微环境；免疫检查点抑制剂；临床试验

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊